On September 17, 2025, Nine Diagnostics placed second in the Longevity Global Pitch Competition at RESI Boston, held at The Westin Copley Place during Biotech Week Boston.
The competition anchored a newly launched longevity and aging track at RESI Boston, organized by Life Science Nation in partnership with The Engine. Six companies delivered seven-minute pitches before a panel of longevity-focused investors, followed by live Q&A.
As part of the second-place prize, Nine Diagnostics received a complimentary one-year Flex-Residency at The Engine for two team members, extending the company’s access to Boston’s Tough Tech incubator and investment community supporting early-stage ventures addressing major scientific and societal challenges.
The recognition reflects growing interest from the longevity investment community in platforms capable of generating a multidimensional biological signal from a single blood draw, an approach with direct relevance to aging biology, functional decline, and early disease detection across both oncology and longevity-adjacent indications.
Nine Diagnostics’ AI-enabled nanosensor platform is built on published peer-reviewed validation. In Nature Nanotechnology (Goerzen et al., 2026), the platform demonstrated 98% accuracy in brain tumor detection and 71% accuracy in tumor type identification across 739 patient samples at Memorial Sloan Kettering Cancer Center, Northwestern University, and NYU, representing the first multi-site clinical validation of the approach. In Nature Biomedical Engineering (Kim et al., 2022), the platform demonstrated 87% sensitivity and 98% specificity for high-grade serous ovarian cancer detection across 269 patient samples.
This work forms the scientific foundation of Nine Diagnostics, co-founded in 2024 by Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.